OBJECTIVE: To probe into the efficacy and safety of ticagrelor in postoperative antiplatelet therapy in elderly patients with percutaneous coronary intervention（ PCI）. METHODS: Clinical data of 202 elderly patients with PCI admitted into Meizhou People’s Hospital from Jan. 2017 to Jun. 2018 were retrospectively extracted. A total of 88 patients treated with aspirin combined with tigrillo were enrolled in the study group and 114 patients treated with clopidogrel were enrolled in the control group. The clinical efficacy

levels of blood C-reactive protein（ CRP） before and after treatment

incidence of adverse drug reactions

and major adverse cardiovascular events after treatment of6 months of two groups were compared. RESULTS: The total effective rate of the study group was 97. 73%（ 86/88）

significantly higher than that of the control group [83. 33%（ 95/114） ]

and the difference was statistically significant（ P<0. 05）. After treatment

the levels of CRP in the study group was significantly lower than that in the control group

and the difference was statistically significant（ P<0. 05）. There were no significant differences in the incidence of arrhythmia

dyspnea

gastrointestinal upset and skin itching between two groups（ P > 0. 05）. After treatment of6 months

the incidence of stent thrombosis in the study group was significantly lower than that in the control group

with statistically significant differences（ P < 0. 05）

while there was no statistically significant difference in the incidence and mortality of myocardial infarction and angina pectoris between two groups（ P>0. 05）. CONCLUSIONS:The efficacy of ticagrelor in postoperative antiplatelet therapy in elderly patients with PCI is significant

which is conducive to reducing the inflammatory response

without increasing the incidence of of adverse drug reactions

and has better prognosis.